Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
Merck announced a $6.7 billion cash deal to acquire Terns Pharmaceuticals, paying a 31% premium and targeting the oral BCR::ABL1 inhibitor TERN‑701 for treatment‑resistant chronic myeloid leukemia. The transaction, slated to close in Q2 2026, adds an orphan‑drug‑designated oncology asset to Merck’s pipeline. Meanwhile, Shionogi agreed to purchase Apnimed’s 50% stake in the Shionogi‑Apnimed Sleep Science joint venture for $100 million upfront plus a $50 million milestone, making SASS wholly owned and freeing Apnimed to focus on its AD109 OSA candidate. Both deals close in the second quarter of 2026 and signal strategic bets on high‑unmet‑need therapeutic areas.
The First Dose Is Everything: Enhancing Adherence and Persistence with Noble SureStartRx™
Noble’s SureStartRx™ program ships remote demonstration kits to patients before their first self‑injectable dose, allowing them to practice and build confidence. The initiative accelerates therapy initiation, improves short‑term adherence, and extends treatment persistence. Director Sean Glynn highlights how this early...
Pharmaceutical Executive Daily: Bayer Shares Drop After Inclusive Capital Offloads Remaining Stake
Inclusive Capital Partners sold its remaining 8.5 million Bayer shares at roughly a 25% discount, raising about $380 million and triggering a 3.7% drop in Bayer’s stock. The exit removes a prominent activist voice as Bayer continues to wrestle with litigation costs...
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
Inclusive Capital Partners, an activist investment firm, sold roughly 8.5 million Bayer shares—about 0.9% of the company—for approximately $379 million. The transaction caused Bayer's stock to tumble around 3% before partially recovering. The sale follows Inclusive Capital’s earlier activism that helped oust...
Why Do Most Pharma Shippers and 3PLs Not Possess the Right Technology to Move From Forecasting to True Agility?
Pharma last‑mile delivery faces unique challenges: chain of custody and strict cold‑chain requirements. Most shippers and 3PLs lack technology to shift from static forecasting to real‑time agility, due largely to compliance costs and legacy routing systems. Advanced IoT sensors, AI‑driven...
Why CMS Is Tightening ASP Reporting and What Manufacturers Must Get Right
CMS will require pharmaceutical manufacturers to submit the "reasonable assumptions" used to calculate their quarterly Average Sales Price (ASP) beginning in 2026. The move formalizes the estimation process that underlies ASP, covering rebates, bundled discounts, free‑goods programs, 340B sales and...
Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer
Pfizer has issued a formal warning to shareholders to reject an unsolicited mini‑tender offer from Tutanota LLC, which seeks to buy up to one million shares at $32 per share—an amount that could be below market value and lacks the...
Pfizer Receives Unsolicited Mini-Tender Offer for 1 Million Shares From Tutanota: Report
Pfizer has warned shareholders to reject an unsolicited mini‑tender offer from Tutanota LLC that seeks to buy up to 1 million shares at $32 per share, roughly 0.02% of its outstanding stock. The offer hinges on Pfizer’s price staying above $32,...
FDA Approves Expanded Indication for Imcivree as Treatment for Hypothalamic Obesity
Rhythm Pharmaceuticals' Imcivree (setmelanotide) received FDA approval as the first treatment for acquired hypothalamic obesity, expanding its indication to adults and children aged four and older. The Phase III TRANSCEND trial demonstrated a 15.8% mean BMI reduction at 52 weeks, an...
What an End-to-End Model Changes for Patients
CareTria is launching an end-to-end patient support model that acts as a single point of contact, promising one‑call resolution and uninterrupted therapy access. The strategy blends AI‑driven automation with human interaction to handle routine tasks while preserving empathy for complex...
How Do Recent Actions From FDA Provide Insight to the Agency's Enforcement Posture?
The FDA’s Rare Disease Evidence Principles (RDEP) introduce flexible trial designs, allowing sponsors to use natural‑history data and novel biomarkers as endpoints. These guidances aim to accelerate approvals for rare‑disease therapies while maintaining safety as a top priority. However, analysts...
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor From Synnovation Therapeutics, Collegium to Acquire Azstarys From Corium Therapeutics
Novartis announced a deal worth up to $3 billion to acquire SNV4818, a pan‑mutant‑selective PI3Kα inhibitor aimed at hormone‑receptor‑positive, HER2‑negative breast cancer. The transaction includes $2 billion upfront and potential milestones exceeding $1 billion, with closing expected in early 2026. Collegium Pharmaceutical agreed...
The Ron Lanton Report: When Policy Becomes a Capital Event
The Ron Lanton Report highlights a fundamental shift where regulatory signals now drive company valuations and strategic choices before formal rules are enacted. Investors are pricing policy risk early, treating anticipated regulations as a capital‑allocation factor. The discussion spans FDA...
What Does Next-Generation Copay Assistance Look Like?
Matthew Turner, President of Patient Affordability at Paysign, says next‑generation copay assistance relies on ecosystem partnerships rather than a single‑vendor model, combining best‑in‑class services such as messaging, hub operations, and nursing education. He highlights financial threats like accumulator and maximizer...
Pharmaceutical Executive Daily: Federal Judge Halts Vaccine Advisory Council Appointments
A federal district court judge issued a preliminary injunction halting the Trump administration’s overhaul of the Advisory Committee on Immunization Practices, finding violations of the Federal Advisory Committee Act and gaps in vaccine expertise. The order pauses pending recommendations on...
How Is eClinical Positioning Its Platform Capabilities to Help Sponsors?
eClinical Solutions is leveraging its elluminate platform to help sponsors adapt to the FDA’s new requirement for a single pivotal trial, a move aimed at strengthening efficacy evidence and patient safety. The platform offers highly customizable centralized monitoring, AI‑driven risk...
Qualified Temperature-Controlled Corridors: The Future Is Here
Qualified Temperature‑Controlled Corridors (TCCs) are emerging as a global standard for shipping temperature‑sensitive pharmaceuticals, integrating regulatory compliance, digital telemetry, and predictive analytics. The model reduces handoffs, minimizes excursion risk, and provides continuous visibility from origin to destination. Industry leaders from...
What Does a Sustainable Affordability Model Look Like in the Current Landscape?
Shivani Patel of ConnectiveRx explains how the Inflation Reduction Act forces pharmaceutical manufacturers to redesign patient‑assistance programs with a focus on gross‑to‑net protection rather than static access solutions. She emphasizes continuous program evaluation, cap adjustments, and alignment with channel‑distribution strategies...
Sentynl Therapeutics Enters Licensing Agreement with PRG S&T to Advance Progerinin
Sentynl Therapeutics, a Zydus Lifesciences subsidiary, has licensed Progerinin, an oral small‑molecule candidate for Hutchinson‑Gilford Progeria Syndrome, from PRG S&T. The agreement grants Sentynl full development rights, making Progerinin its second HGPS therapy and giving it orphan‑drug status from the FDA....
Pharmaceutical Executive Daily: FDA Expands Approval for Arexvy
A West Health‑Gallup survey reveals that over 82 million Americans have reduced daily spending to afford healthcare, highlighting deepening affordability pressures across income levels. The FDA has broadened GSK’s RSV vaccine Arexvy to cover high‑risk adults aged 18‑49, a group responsible...
Pharmaceutical Executive Daily: Senate Democrats Seeking Information on MFN Pharma Deals
Senate Democrats, led by Sen. Ron Wyden, have sent letters to eleven pharmaceutical companies demanding details on their most‑favored‑nation (MFN) agreements and whether those prices generate real savings for Medicaid, with a March 23 response deadline. The inquiry follows earlier requests...
Navigating Complexity in Emerging Biotech: Innovations, Integrations, and Initial Hurdles
Industry experts highlight three intersecting forces reshaping emerging biotech: the persistent funding and regulatory hurdles faced by early‑stage startups, the rapid migration of AI from a supportive tool to an operational backbone, and breakthrough computational methods—including quantum chemistry—that are redefining...
Moving CAR-T Beyond Oncology
Researchers are expanding CAR‑T cell therapy beyond cancer to treat autoimmune diseases such as lupus and rheumatoid arthritis. Sail Biomedicine’s chief products and operations officer highlighted on the Pharmaceutical Executive podcast that the company has pivoted to RNA‑based CAR‑T platforms,...
Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development
The FDA issued its fourth revision of draft biosimilar development guidance, allowing scientifically justified streamlining of pharmacokinetic (PK) studies and estimating up to a 50% cost reduction—about $20 million per program. The new guidance also expands the use of clinical data...
Orphan Product Risk Contracting
Ira Studin warns that while current policies such as TrumpRx and Medicare negotiations exempt orphan drugs, emerging mechanisms like most‑favored‑nation (MFN) pricing and pharmacy‑benefit‑manager (PBM) net pricing could introduce downward pressure. He argues manufacturers should evaluate risk‑contracting to safeguard pricing,...
When Ambition Meets Ambiguity: The Trends and Sentiments Shaping Biotech in 2026
ICON Biotech’s 2025 survey of 163 global biotech leaders, plus 100 Chinese executives, reveals shifting dynamics as China overtakes the United States in innovative trial volume and is projected to contribute 35% of FDA approvals by 2040. Funding remains scarce,...
Pharmaceutical Executive Daily: FDA Expands Approval of Leucovorin
The FDA has expanded approval of leucovorin calcium tablets as the first therapy for cerebral folate transport deficiency linked to FOLR1 gene variants. The decision relied on published case literature, showing 87‑89% of patients achieved clinical improvement. In oncology, AstraZeneca...
How FDA's Removal of the Two-Trial Requirement Affects Development Programs
The FDA has eliminated the longstanding requirement for two pivotal clinical trials, adopting a single‑trial default to speed drug approvals. The agency pairs this change with a mandate for more rigorous post‑market surveillance to catch safety signals after launch. Pharmaceutical...
AI Has Redefined Healthcare Communication — and There’s No Opting Out
Conversational AI tools such as ChatGPT Health and Claude for Healthcare are reshaping how patients and clinicians obtain medical information. OpenAI reports that over 5% of global ChatGPT interactions—about 40 million daily users—are health‑related, while 40% of U.S. healthcare workers use...
Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time
Vinay Prasad has left the FDA’s Center for Biologics Evaluation and Research (CBER) for the second time in under a year, signaling a notable leadership turnover at a key regulatory hub for biologics, vaccines and gene therapies. In parallel, GlaxoSmithKline...
The Impact of a CRM Transition: Q&A with David Rosner
Pharma firms must choose between Veeva and Salesforce CRMs after the vendors split, creating a roughly even market split among the top 20 life‑science companies. Deloitte’s David Rosner says the decision is more than a tech upgrade; it can reshape...
Key Factors Contributing to Uncertainty in Moderna's mRNA Vaccine Review
The FDA initially refused to review Moderna’s mRNA‑based flu vaccine, prompting surprise among industry observers. After a White House meeting, the agency reversed course and granted Moderna a Type A meeting, effectively resetting the review process. Lanton notes this regulatory flip‑flop...
From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma
The article outlines a four‑step framework for specialty pharma companies to redesign market‑access strategies as they move from approval to commercial launch. It stresses securing payer formulary placement, deploying a focused sales force, establishing a trusted pharmacy network, and centering...
Consent‑Driven Targeting: Building Trust With Patients and HCPs
Life‑science marketers face mounting pressure to deliver personalized content while meeting stricter privacy regulations such as CCPA and the EU Data Act. Companies are shifting from static consent checkboxes to unified, real‑time consent frameworks that synchronize preferences across CRM, CDP,...
Pharmaceutical Executive Daily: Cognito Therapeutics and Nexcure Secure Financing Rounds
Cognito Therapeutics closed an oversubscribed $105 million Series C round to fast‑track its neurodegenerative programs, while Nexcure raised $19 million in a Series A to fund its immunology pipeline. At the same time, artificial‑intelligence advances—particularly large language models—are reshaping pharmacovigilance by automating analysis of...
Pharma Funding Roundup: Cognito Therapeutics Closes Oversubscribed $105 Million Series C Financing, Nexcure Launches $19 Million Series A Financing
Cognito Therapeutics closed an oversubscribed $105 million Series C round to fund its at‑home Alzheimer’s stimulation device, Spectris, targeting a 2027 market launch after a pivotal readout. NexCure raised $19 million in a Series A to build an outpatient platform that standardizes and expands...
The Ongoing Impact of MFN Pricing
The pharmaceutical industry is grappling with evolving Most‑Favored‑Nation (MFN) pricing rules as the TrumpRx initiative clarifies administration expectations. Recent Supreme Court rulings on IEEPA tariffs, distinct from Section 232 tariffs used in MFN negotiations, add uncertainty to pricing strategies. Manufacturers must...
Pharmaceutical Executive Daily: Pharma Industry's AI Adoption
Pharmaceutical companies are striking major deals while accelerating AI integration. Antengene and UCB signed a global licensing agreement worth roughly $1 billion to develop a bispecific T‑cell engager for cancer therapy. Teva Pharmaceutical Industries secured a $400 million strategic growth capital partnership...
Antengene and UCB Enter $1.18 Billion Global License Agreement for Bispecific T-Cell Engager
Antengene and UCB have signed a global license agreement to develop ATG‑201, a CD19/CD3 bispecific T‑cell engager targeting B‑cell‑driven autoimmune diseases. The deal delivers an $80 million upfront payment and unlocks more than $1.1 billion in development and commercial milestones, plus tiered...
Teva and Blackstone Life Sciences Enter $400 Million Strategic Growth Capital Agreement
Teva Pharmaceuticals has secured a $400 million strategic growth capital agreement with Blackstone Life Sciences to fund the Phase III development of duvakitug, a TL1A‑targeting monoclonal antibody for ulcerative colitis and Crohn’s disease. The four‑year deal grants Blackstone milestone payments and low‑single‑digit...
FDA's History with Complex Plants
The FDA issued its first botanical drug guidance in 2004 and updated it in 2016, yet only four complex plant‑derived drugs have been approved to date. Ajna Biosciences, led by Joel Stanley, has secured clearance to begin a Phase 2 trial...
Enhancing Cold Chain Visibility
SpotSee introduced WarmMark QR, a battery‑free, QR‑enabled temperature sensor designed for cold‑chain logistics. The device delivers affordable, real‑time, package‑level temperature data, replacing error‑prone visual indicators. By allowing remote data access, it improves recipient adoption and streamlines monitoring for shippers. The...
Pharmaceutical Executive Daily: Novo Nordisk Commits $506 Million to Ireland Manufacturing Site
Novo Nordisk announced a $506 million investment to expand its manufacturing site in Ireland, aiming to boost capacity for diabetes and obesity therapies. The expansion addresses rising global demand and enhances supply‑chain resilience. The announcement coincides with industry focus on measuring...
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
Patent term extension (PTE) offers up to five extra years of exclusivity for FDA‑approved drugs, but biologics present a unique hurdle because the law hinges on defining the “active ingredient.” Unlike small molecules, biologics are large, variable structures, making it...
Real-World Data Brings New Insights to Natural History of Disease Studies
Real‑world data (RWD) is reshaping natural history studies by delivering longitudinal, patient‑level information that was previously only obtainable through costly prospective trials. Advances in artificial intelligence and natural language processing now allow rapid extraction of structured data from unstructured sources...
Pharmaceutical Executive Daily: FDA Approves Hernexeos
The FDA approved Hernexeos through the national priority voucher program, a mechanism that fast‑tracks drugs addressing unmet medical needs. Industry leaders are evaluating direct‑to‑consumer (DTC) models to broaden access to HIV prevention tools, leveraging digital and telehealth channels. Additionally, the...
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
Gilead’s U.S. HIV prevention VP Ashley Gildea unveiled a direct‑to‑consumer campaign for Yeztugo, the first twice‑yearly injectable PrEP. The campaign, anchored by a music‑driven “One2PrEP” spot, aims to lift awareness among the estimated 2.2 million Americans who could benefit from PrEP...
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO
Sarepta Therapeutics announced that CEO Douglas Ingram will retire by the end of 2026, triggering a formal succession search. The move follows a turbulent 2025 in which the company’s flagship gene therapy Elevidys was linked to two patient deaths, prompting...
What Does the Rollout of Trump Rx Reveal?
Buzz Health President Joseph Kleiman says TrumpRx is advancing drug‑price transparency by giving consumers early visibility into prescription costs. He notes that real‑time pricing can help patients compare options but also warns that prices are dynamic and may change before...
Leading in the Psychedelic Space: Q&A with Tarek Rabah
Otsuka America became the first major pharmaceutical company to back psychedelic‑inspired medicines in 2020 through a partnership with COMPASS Pathways, and deepened that commitment by acquiring Mindset in 2023. The company is applying its long‑standing CNS expertise to develop serotonergic...